So you are saying that such technique will cause atherosclerosis and hemorrhage diathesis even in young as a side effect?
As I said long ago, India's plan is to produce more cheap labour to reduce cost of production and this has caused this. Indians are enemy of Indians. 70 years of India doomed India. I wish Modi ji before stepping down does teach commonsense to people of this nation. No one cares for any one there. Human life has no value in India. Be it soldiers, senior citizens , kids. Sala mazaak bana ke rakh diya hai desh ka.
12-year-old dies after walking for more than 100 km from Telangana to Chhattisgarh
Bijapur (Chhattisgarh) [India], April 21 (ANI): in a heart-wrenching incident, a 12-year-old girl collapsed and died of sheer exhaustion after walking for 3 days continuously covering 100 kilometres from Telangana back home to Chhattisgarh during the national lockdown.www.aninews.in
The recovery period , for the economy will be long
If Modi does not handle it properly
He will loose badly
Bihar elections will be a Test case for Modi
Because Migrants are not happy at being locked up
Wait and watch
Nah. Its not a side effect.
Example. A 25 years old woman presented to ER with absolutely no prior history of any kind of illness/disease or any sign or symptom except a feeling of relative breathlessness since 2 hours and no other accompanying sign/symptom. Evaluated for COVID, the complete bloodwork and biochem panel was sent. Chest Xray revealed no abnormal finding. By 12 she had been intubated on back of falling Blood Oxygen saturation (and inability to maintain on non invasive ventilation) and by 2 pm, she was declared dead. By 4 pm findings of COVID positive came.
Another. 30 years old presented with loss of consciousness, progressive weakness starting in right lower limb than right upper limb then involving the left side in similar way. Evaluated to be diagnosed as Ischemic Stroke. No other history or abnormality. Found to be CoVID positive on a random test.
Next. Patient, diabetic and with slight derangement of renal parameters - not needing dialysis, presented for complaints of pain abdomen. Chest X Ray normal, CT abdomen revealed Ischemic Bowel. CT chest was done at same time - suspicion of COVID. Tested poisitive
I can go on ... its a splatter job.
The Virus has properties of Corona Virus with S protein enabling attachment to the ACE2 receptors and easier penetration into the organs. Additionally, GP41 .. the HIV Glycoprotein. It acts like a HIV virus too
This is bizzare!!
So the patient was asymptomatic most of the time until the breathlessness started. Normally It has been noticed that breathlessness followed by tachycardia are also the symptoms of Covid. Normally tachycardia happens while recovering but I am not sure if that had been the cause of hypoxemia. Would an ECG helped?
Then basically the virus is affecting randomly where ever it gets access to. Because the way people are describing symptoms the list is just getting longer. It's showing TB type symptoms, some times malaria or meningitis.
What I think it's total activation period in a particular climate or community is 1-3 months and then the RNA becomes inactive after mutation, due to a fix timing in circadian clock. This seem to be a lab mutated pathogen.
You could try this approach to food provision.PoK residents urge India to send food amid shortages
PoK residents urge India to send food amid shortages
No medical facilities are available in parts of PoK. Besides a bag of 20 kg flour which was under Pakistani Rupees 700 (Indian rupees 350 approx) per bag before Corona virus struck the region is now being sold at more than Pakistani Rupees 1200 a bag. Flour mills from Pakistans Punjab province...m.economictimes.com
@_Anonymous_
@safriz @Arsalan123 Imran Khan's Naya Pakhanistan not even able to provide food to PoK residents....
This is starting to have all the hallmarks of an engineered virus.
21 million Chinese died of Covid: US intelligence
theeasternlink.com
21 million Chinese died of Covid: US intelligence - The Eastern Link
A new data intercepted by the United States reveals that 21 million people died in China from December 2019 to March 2020, US intelligence officials conclude in a classified report for the Trump administration. The Intelligence report stated that at least 20.9 million of the deaths were linked...
theeasternlink.com
21 million Chinese died of Covid: US intelligence
21 million Chinese died of Covid: US intelligence - The Eastern Link
A new data intercepted by the United States reveals that 21 million people died in China from December 2019 to March 2020, US intelligence officials conclude in a classified report for the Trump administration. The Intelligence report stated that at least 20.9 million of the deaths were linked...
Obviously fake news.
It's just subscribers switching to 5G.
China Mobile reaches 15.4 million 5G subscribers at end-February
China Mobile previously said that it is aiming to have a total of 300,000 5G base stations across the country by the end of 2020.
www.rcrwireless.com
Cadila believes it has silver bullet to fight COVID-19
By Sohini Das
April 21, 2020 12:11 IST
Image has been posted only for representational purposes. Photograph: PTI Photo
Ahmedabad-based pharmaceutical major Cadila Healthcare has emerged at the forefront of India's battle to fight the coronavirus disease.
After announcing research on two vaccine candidates, work on developing rapid diagnostic kits and ramping up production of hydroxychloroquine, the company is now exploring the use of a biologic drug Interferon alfa-2b to treat COVID-19.
Recent studies have shown evidence of a direct antiviral effect of Interferon alfa-2b against the new coronavirus.
Cadila Healthcare (Zydus Cadila) has been commercially making Pegylated Interferon alfa-2b under the brand name Pegihep since 2011 for the treatment of Hepatitis B and C, with 150,000 doses being administered.
Pegihep is not yet licensed or approved for the treatment of COVID-19. However, it can be used as a 'compassionate use programme'.
Zydus has approached the department of biotechnology to investigate the role of Pegylated Interferon alfa-2b for COVID-19 and is ready to undertake clinical trials.
In-vitro studies have demonstrated that Interferon alfa-2b has antiviral effect against the novel coronavirus.
One study by the University of Texas Medical, Galveston, demonstrated around 10,000-fold reduction in-virus titre in cells that were pre-treated with Interferon alfa-2b 48 hours earlier.
The second by a group of universities in China, Australia, and Canada retrospectively analysed 77 moderate COVID-19 subjects in Wuhan and observed that those who received Interferon alfa-2b showed significant reduction in the duration of virus-shedding period and even in levels of the inflammatory Cytokine IL-6.
This suggests that if a long-acting molecule like Pegylated Interferon alfa-2b is given early on in the infection, the patient suffering from COVID-19 will have significant benefit, as the viral load is reduced, lesser inflammatory elements are produced, and the virus-eliminating specific immune response is generated.
When the human body contracts an infection due to a viral attack, it produces a group of molecules called Type 1 interferons as a first line of defence.
Interferon alfa-2b is one such Type 1 Interferon molecule that not only slows down the viral replication, but also helps activate the two arms of our immune system -- Innate, for immediate killing of the virus, and Adaptive, for long-lasting immunity.
To make it more effective, the molecule is coupled with polyethylene glycol to produce a new molecule called Pegylated Interferon alfa-2b that has the same functionality as Interferon alfa-2b, but remains in the body longer and therefore, requires only once-a-week injection, thus, providing a much better efficacy profile.
"Pegylated Interferon alfa-2b emerges as one such possibility with its potential to reduce virus titres when given earlier in the disease and offering better clinical outcomes," says Sharvil Patel, managing director, Cadila Healthcare.
"We are working with the US Food and Drug Administration and have opened an investigational new drug filing for Pegylated Interferon alpha-2b for the treatment of COVID-19," says Patel.
Apart from Interferon, the company has already increased its capacity to make both raw material and formulation of hydroxychloroquine after the drug was touted as useful by several countries as a preventive to be used by health care professionals and patient caregivers.
"This month we are making 10 tonnes of the API that can make 100 million tablets and next month we will make 30 tonnes of the API that will make another 150 million tablets," says Pankaj Patel, chairman, Zydus Cadila.
As a temporary measure, production of hydroxychloroquine is happening at its Ahmedabad plant. Pankaj Patel says the Centre has procured around 100 million tablets and states together have procured 60 million to 70 million tablets.
It is also working on an accelerated vaccine development programme which is currently in the animal testing stage and if the results are successful, it should enter clinical studies in the second quarter of this financial year.
Zydus has two vaccine candidates -- a DNA vaccine -- and another, a live weakened recombinant measles vaccine against COVID-19.
Zydus recently got approval to import rapid antibody kits for COVID-19 diagnosis from China, and is working to develop an indigenous kit.
Cadila believes it has silver bullet to fight COVID-19
By Sohini Das
April 21, 2020 12:11 IST
Image has been posted only for representational purposes. Photograph: PTI Photo
Ahmedabad-based pharmaceutical major Cadila Healthcare has emerged at the forefront of India's battle to fight the coronavirus disease.
After announcing research on two vaccine candidates, work on developing rapid diagnostic kits and ramping up production of hydroxychloroquine, the company is now exploring the use of a biologic drug Interferon alfa-2b to treat COVID-19.
Recent studies have shown evidence of a direct antiviral effect of Interferon alfa-2b against the new coronavirus.
Cadila Healthcare (Zydus Cadila) has been commercially making Pegylated Interferon alfa-2b under the brand name Pegihep since 2011 for the treatment of Hepatitis B and C, with 150,000 doses being administered.
Pegihep is not yet licensed or approved for the treatment of COVID-19. However, it can be used as a 'compassionate use programme'.
Zydus has approached the department of biotechnology to investigate the role of Pegylated Interferon alfa-2b for COVID-19 and is ready to undertake clinical trials.
In-vitro studies have demonstrated that Interferon alfa-2b has antiviral effect against the novel coronavirus.
One study by the University of Texas Medical, Galveston, demonstrated around 10,000-fold reduction in-virus titre in cells that were pre-treated with Interferon alfa-2b 48 hours earlier.
The second by a group of universities in China, Australia, and Canada retrospectively analysed 77 moderate COVID-19 subjects in Wuhan and observed that those who received Interferon alfa-2b showed significant reduction in the duration of virus-shedding period and even in levels of the inflammatory Cytokine IL-6.
This suggests that if a long-acting molecule like Pegylated Interferon alfa-2b is given early on in the infection, the patient suffering from COVID-19 will have significant benefit, as the viral load is reduced, lesser inflammatory elements are produced, and the virus-eliminating specific immune response is generated.
When the human body contracts an infection due to a viral attack, it produces a group of molecules called Type 1 interferons as a first line of defence.
Interferon alfa-2b is one such Type 1 Interferon molecule that not only slows down the viral replication, but also helps activate the two arms of our immune system -- Innate, for immediate killing of the virus, and Adaptive, for long-lasting immunity.
To make it more effective, the molecule is coupled with polyethylene glycol to produce a new molecule called Pegylated Interferon alfa-2b that has the same functionality as Interferon alfa-2b, but remains in the body longer and therefore, requires only once-a-week injection, thus, providing a much better efficacy profile.
"Pegylated Interferon alfa-2b emerges as one such possibility with its potential to reduce virus titres when given earlier in the disease and offering better clinical outcomes," says Sharvil Patel, managing director, Cadila Healthcare.
"We are working with the US Food and Drug Administration and have opened an investigational new drug filing for Pegylated Interferon alpha-2b for the treatment of COVID-19," says Patel.
Apart from Interferon, the company has already increased its capacity to make both raw material and formulation of hydroxychloroquine after the drug was touted as useful by several countries as a preventive to be used by health care professionals and patient caregivers.
"This month we are making 10 tonnes of the API that can make 100 million tablets and next month we will make 30 tonnes of the API that will make another 150 million tablets," says Pankaj Patel, chairman, Zydus Cadila.
As a temporary measure, production of hydroxychloroquine is happening at its Ahmedabad plant. Pankaj Patel says the Centre has procured around 100 million tablets and states together have procured 60 million to 70 million tablets.
It is also working on an accelerated vaccine development programme which is currently in the animal testing stage and if the results are successful, it should enter clinical studies in the second quarter of this financial year.
Zydus has two vaccine candidates -- a DNA vaccine -- and another, a live weakened recombinant measles vaccine against COVID-19.
Zydus recently got approval to import rapid antibody kits for COVID-19 diagnosis from China, and is working to develop an indigenous kit.
Cadila believes it has silver bullet to fight COVID-19
The so called islamophobia is being circulated because non muslims have started complete boycott of muslim traders/ street vendors. This is pinching them real hard and most poor muslims are afraid of their livelihood now. These pics of muslims spitting/urinating on food stuff they sell have really reached nearly every non muslim. It will have very serious consequences for muslim traders.
It is. It has inserted sequences rendering properties of SARS CoV 1 and HIV to it. Would not be possible by random natural recombination. Too much of a coincidence.
Chinese were using Remdisivir straight away to treat this virus. This shows that they knew what exactly this virus is.
Mumbai Coronavirus News: 25-year-old with no conditions dies after 3 days in hospital | Mumbai News - Times of India
A week ago, 25-year-old Pradip Mali was a doting father to his one-and-half-yearold son, a loving husband and a caring son to his parents. On April 14
www.google.com
This sad news shows that even the YOUTH. are also likely to die